BioSpace - Print News Article

BD Biosciences (BDX) New Product Quickly and Easily Detects Intracellular and Intranuclear Proteins 5/21/2012 11:11:14 AM May 21, 2012 -- BD Biosciences, a segment of BD (Becton, Dickinson and Company), recently launched the BD Pharmingen™ Transcription Factor Buffer Set, a fixation and permeabilization buffer for the detection of intracellular and intranuclear proteins by flow cytometry. Transcription factors are important proteins for development and cell differentiation. The BD Pharmingen Transcription Factor Buffer Set was designed to improve ease-of-use and minimize processing time. This increases the resolution of positively stained cells while reducing nonspecific staining and cell loss during fixation, permeabilization and staining procedures. Flow cytometric detection of many proteins known to be expressed within various intracellular compartments, especially transcription factors, is improved with this new product. The BD Pharmingen Transcription Factor Buffer Set offers: - Improved sensitivity for many transcription factors, including FoxP3, RORyt and T-bet - Improved cell recoveries - Compatibility with many cell types, cell surface staining, and tandem dyes - High-throughput testing via volume reduction, bulk fixing, and storage For more information on the BD Pharmigen Transcription Factor Buffer Set, please visit http://www.bdbiosciences.com/go/tfbuffer. About BD BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.

BD Biosciences (BDX) New Product Quickly and Easily Detects Intracellular and Intranuclear Proteins
5/21/2012 11:11:14 AM

May 21, 2012 -- BD Biosciences, a segment of BD (Becton, Dickinson and Company), recently launched the BD Pharmingen™ Transcription Factor Buffer Set, a fixation and permeabilization buffer for the detection of intracellular and intranuclear proteins by flow cytometry. Transcription factors are important proteins for development and cell differentiation.

The BD Pharmingen Transcription Factor Buffer Set was designed to improve ease-of-use and minimize processing time. This increases the resolution of positively stained cells while reducing nonspecific staining and cell loss during fixation, permeabilization and staining procedures. Flow cytometric detection of many proteins known to be expressed within various intracellular compartments, especially transcription factors, is improved with this new product.

The BD Pharmingen Transcription Factor Buffer Set offers:

- Improved sensitivity for many transcription factors, including FoxP3, RORyt and T-bet

- Improved cell recoveries

- Compatibility with many cell types, cell surface staining, and tandem dyes

- High-throughput testing via volume reduction, bulk fixing, and storage

For more information on the BD Pharmigen Transcription Factor Buffer Set, please visit http://www.bdbiosciences.com/go/tfbuffer.

About BD

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.